The total funding comprises US$1 million in angel investment and a US$4 million seed round. The seed financing round was led by Wavemaker Ventures, with participation by SEEDS, further supported by notable investors across the United States and Asia.

总融资额包括100万美元的天使投资和400万美元的种子轮融资。种子轮融资由Wavemaker Ventures领投，SEEDS跟投，并得到了来自美国和亚洲的知名投资者的进一步支持。

The financing will support the continued expansion of ChemT's AI and experimental infrastructure, which aims to make advanced medicines easier to manufacture, scale, and deliver to patients worldwide.

这笔融资将支持ChemT持续扩展其人工智能和实验基础设施，旨在使先进药物的制造、规模化生产以及向全球患者交付变得更加便捷。

SINGAPORE

新加坡

,

，

June 22, 2026

2026年6月22日

/PRNewswire/ -- ChemT Biotechnology, an AI-driven biotechnology company building the intelligence layer for biomanufacturing, has closed a US$4 million seed round led by Wavemaker Ventures, the early-stage fund of Wavemaker Partners, with participation from co-investment partner SEEDS, an arm of SG Growth Capital, the investment platform of EDB and Enterprise Singapore.

/美通社/ -- ChemT Biotechnology 是一家由人工智能驱动的生物科技公司，致力于为生物制造构建智能层。该公司已完成400万美元的种子轮融资，本轮融资由 Wavemaker Partners 旗下的早期基金 Wavemaker Ventures 领投，SG Growth Capital（新加坡经济发展局 EDB 和新加坡企业发展局 Enterprise Singapore 的投资平台）旗下机构 SEEDS 作为联合投资伙伴参与跟投。

The round was further supported by notable investors across the United States and Asia, including Wavemaker 360 Health, Draper University Ventures, and Temasek Life Sciences Accelerator..

本轮融资还获得了来自美国和亚洲的知名投资者的进一步支持，包括 Wavemaker 360 Health、Draper University Ventures 和淡马锡生命科学加速器（Temasek Life Sciences Accelerator）。

Making biologics at scale is harder than it looks. Manufacturers face long development timelines, unpredictable yields, high costs, and processes that are difficult to scale, all of which slow the delivery of treatments to patients. At the heart of the problem is that we lack precise and tunable ways to manipulate cells - the mini factories where important biologics are made. .

大规模生产生物制品比看起来更加困难。制造商面临着漫长的开发周期、不可预测的产量、高昂的成本以及难以放大的生产工艺，所有这些因素都延缓了治疗药物向患者的交付。问题的核心在于，我们缺乏精确且可调控的手段来操控细胞——这些细胞是生产重要生物制品的微型工厂。

ChemT is taking a different approach. Unlike conventional AI drug discovery companies or lab automation tools, ChemT builds intelligence directly into the manufacturing process itself, helping companies better understand the cells behind biomanufacturing, and provides a new way to guide cell behavior for faster, more scalable, and reliable production..

ChemT 采取了一种不同的方法。与传统的 AI 药物发现公司或实验室自动化工具不同，ChemT 将智能直接嵌入到制造过程本身中，帮助公司更好地理解生物制造背后的细胞，并提供一种新的方式来引导细胞行为，以实现更快、更具可扩展性且更可靠的生产。

At the heart of the company is CelMo™, an AI-driven Virtual Cell platform trained on billions to trillions of proprietary biological sequencing reads and validated in the lab. CelMo™ is designed to simulate how cells respond to manufacturing conditions, genetic changes, and other stresses. By tracking which biological processes inside a cell are being activated, suppressed, or rewired, from growth and metabolism to stress response and productivity, CelMo™ builds a dynamic picture of how cell states shift throughout manufacturing.

公司的核心是 CelMo™，这是一个由人工智能驱动的虚拟细胞平台，基于数十亿至数万亿条专有生物测序读段进行训练，并经过实验室验证。CelMo™ 旨在模拟细胞对制造条件、基因变化及其他应激因素的反应。通过追踪细胞内从生长和代谢到应激反应和生产效率等生物过程的激活、抑制或重连情况，CelMo™ 构建了在整个制造过程中细胞状态变化的动态图景。

Built on this foundation are practical applications: identifying target cell pathways to improve manufacturing performance, designing small molecules to guide cell behavior, and supporting cell engineering using AI..

在此基础上建立了实际应用：识别靶细胞通路以提高制造性能，设计小分子以引导细胞行为，并利用人工智能支持细胞工程。

CelMo™ is already delivering results. In CHO cells, the cell type most commonly used to manufacture antibodies and therapeutic proteins, the platform has demonstrated a 50% increase in antibody output and a 40% reduction in production timelines.

CelMo™ 已初见成效。在常用于生产抗体和治疗性蛋白质的 CHO 细胞中，该平台使抗体产量提高了 50%，并将生产周期缩短了 40%。

ChemT's flagship small molecule product, Chemplify™, applies the same approach to T-cell manufacturing, a critical component of advanced cancer therapies. Chemplify™ has demonstrated 50% faster development, 3× scalability, 60% lower costs, and 10× higher cell expansion yield.

ChemT的旗舰小分子产品Chemplify™将相同的方法应用于T细胞制造，这是先进癌症疗法的关键组成部分。Chemplify™已展现出开发速度加快50%、可扩展性提高3倍、成本降低60%以及细胞扩增产量提高10倍的显著优势。

'This financing is a strong validation of our team, our technology, and our mission during a difficult funding environment for life sciences,' said Jie Sun, co-founder and CEO of ChemT Biotechnology. 'Within roughly a year and half of launch, we've built commercial partnerships with more than 40 pharmaceutical, biotech, and CDMO companies across the globe.

“在生命科学领域融资环境艰难的背景下，此次融资有力地验证了我们的团队、技术和使命。”ChemT Biotechnology联合创始人兼首席执行官孙杰表示，“在成立大约一年半的时间里，我们已与全球40多家制药、生物科技和CDMO企业建立了商业合作伙伴关系。”

The future of biomanufacturing will not be won by automation alone -- it will require intelligence.'.

生物制造的未来不会仅靠自动化赢得——它需要智能。

The financing will support the continued expansion of ChemT's AI and experimental infrastructure, advancement of its AI-designed molecular products toward GMP standards and regulatory readiness, scaling of commercial partnerships, and further development of CelMo™. ChemT plans to expand the platform beyond CHO cells and T cells into other cellular systems, including stem cells, NK cells (Natural Killer cells, used in next-generation cancer immunotherapies), and HEK cells (Human Embryonic Kidney cells, widely used in gene therapy and biologics production), enabling broader intelligent control across biomanufacturing workflows..

本次融资将支持ChemT持续扩展其人工智能和实验基础设施，推动其AI设计的分子产品达到药品生产质量管理规范（GMP）标准并满足监管要求，扩大商业合作伙伴关系，以及进一步推进CelMo™的开发。ChemT计划将该平台的应用范围从CHO细胞和T细胞扩展到其他细胞系统，包括干细胞、NK细胞（自然杀伤细胞，用于下一代癌症免疫疗法）和HEK细胞（人胚肾细胞，广泛用于基因治疗和生物制品生产），从而在生物制造工作流程中实现更广泛的智能控制。

'Our customers come to us because they are stuck - development timelines stretch for years, processes break when you try to scale them,'

“我们的客户找到我们，是因为他们陷入了困境——开发周期一拖就是几年，一旦尝试规模化，流程就会崩溃。”

said Dr. Ling Wu, co-founder and President of ChemT Biotechnology.

ChemT Biotechnology联合创始人兼总裁吴玲博士表示。

'CelMo™ is the cellular world model to understand what's happening inside their cells and intervene intelligently. Our goal is to help make advanced medicines easier to manufacture, scale, and deliver to patients worldwide.'

CelMo™ 是一款细胞世界模型，旨在帮助人们理解细胞内部的变化并进行智能干预。我们的目标是让先进药物的制造、规模化生产以及向全球患者交付变得更加便捷。

'Biomanufacturing has long been constrained by structural bottlenecks, rooted in the lack of computational understanding of how cellular networks behave inside

生物制造长期以来受到结构性瓶颈的制约，其根源在于缺乏对细胞网络内部行为机制的计算理解

bioreactors

生物反应器

. ChemT addresses this through precision small molecules that modulate cellular behavior — giving manufacturers a new lever for faster, cheaper, and higher-yield production with consistent quality,'

ChemT 通过能够调节细胞行为的精密小分子来解决这一问题，为制造商提供了一种新手段，以实现更快、更经济、更高产且质量稳定的生产。

said Paul Santos, Co-founder and Managing Partner of Wavemaker Partners.

Wavemaker Partners 联合创始人兼管理合伙人 Paul Santos 表示。

'We look forward to working with ChemT's founding team, which brings together technical and commercial depth, scientific credibility, world-class bioprocess leadership, and capital efficiency — a rare combination that has already drawn early commercial partnerships from all over the world.'

“我们期待与ChemT的创始团队携手合作，该团队兼具技术与商业深度、科学公信力、世界级的生物工艺领导能力以及资本效率——这种罕见的组合已经吸引了来自全球的早期商业合作伙伴。”

About ChemT Biotechnology

关于ChemT生物技术

ChemT Biotechnology is an AI-driven biotech company based across Singapore and the United States, building the intelligence layer for biomanufacturing. Its CelMo™ Virtual Cell platform combines AI, proprietary biological data, and wet-lab validation to better understand and guide cell behavior in biomanufacturing. .

ChemT Biotechnology 是一家由人工智能驱动的生物科技公司，总部位于新加坡和美国，致力于构建生物制造领域的智能层。其 CelMo™ 虚拟细胞平台融合了人工智能、专有生物数据以及湿实验验证，旨在更深入地理解并指导生物制造中的细胞行为。

Contact

联系

For more information, please contact

如需更多信息，请联系

[email protected]

[email protected]

or visit

或访问

https://www.chemtbio.com/

https://www.chemtbio.com/

ChemT is having an upcoming product and model launch and showcase online, to register your interest - please click

ChemT 即将在线举办新品及模型发布与展示活动，如需登记意向，请点击

here

这里

!

！

SOURCE ChemT Biotechnology

来源：ChemT 生物技术

21

二十一

%

%

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示